{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Zim Laboratories Ltd
Zim Laboratories Faces Intense Selling Pressure Amid Consecutive Losses
Zim Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, is currently experiencing severe selling pressure with no buyers in the queue, signalling distress selling and a challenging market environment for the stock.
Zim Laboratories Faces Selling Pressure with Year-to-Date Losses of 31.56% Amid Declines
Zim Laboratories Ltd is experiencing significant selling pressure, marked by consecutive days of losses. While it has shown a modest weekly gain, its longer-term performance is troubling, with notable declines over three months, year-to-date, and the past year, reflecting broader market trends and potential company-specific challenges.
Zim Laboratories Faces Financial Challenges Amidst Mixed Market Performance Trends
Zim Laboratories has reported a challenging financial quarter ending September 2025, with significant declines in profit before tax and profit after tax. Key metrics show low return on capital employed and reduced cash reserves, alongside a rising debt-equity ratio, indicating heightened financial concerns amid mixed market performance.
Zim Laboratories Q2 FY26: Losses Deepen Amid Revenue Recovery
Zim Laboratories Ltd., a Nagpur-based pharmaceutical formulations manufacturer, reported a net loss of ₹0.42 crores for Q2 FY26, marking a sharp deterioration from the previous quarter's loss of ₹1.87 crores and reversing the profit of ₹2.38 crores recorded in Q2 FY25. The company, with a market capitalisation of ₹354.00 crores, saw its stock trading at ₹74.33 on November 14, 2025, down 31.11% over the past year despite a modest 1.79% gain on the day.
How has been the historical performance of Zim Laboratories?
Zim Laboratories' historical performance shows fluctuating financial metrics, with net sales at 379.03 Cr in March 2025, a slight increase from the previous year but a decrease from March 2023. Key figures include a rise in operating profit to 49.50 Cr, while profit before tax and profit after tax fell to 18.01 Cr and 12.17 Cr, respectively.
Why is Zim Laboratories falling/rising?
As of 13-Nov, Zim Laboratories Ltd's stock price is Rs 72.67, down 5.5%, with a year-to-date decline of 32.08%. Despite a recent short-term gain of 2.60%, the stock has significantly underperformed over the long term, dropping 76.82% in three years compared to the Sensex's growth.
How has been the historical performance of Zim Laboratories?
Zim Laboratories has shown mixed historical performance, with net sales increasing slightly to 379.03 Cr in March 2025 but declining in profitability, with profit after tax dropping to 12.17 Cr. While total assets rose, cash flow management remains a challenge, with a net cash outflow of -7.00 Cr in March 2025.
Why is Zim Laboratories falling/rising?
As of 11-Nov, Zim Laboratories Ltd's stock price is at 77.62, up 10.15% today, but down 27.46% year-to-date. While it has outperformed the Sensex recently, its long-term performance remains weak.
Zim Laboratories Ltd Sees 0.63% Gain Today Amid Broader Market Decline, Still Down 34.33% YTD
Zim Laboratories Ltd is experiencing increased buying activity, showing a slight gain today while the Sensex declines. Despite this, the stock has faced recent losses and significant declines over the past year, remaining below key moving averages, indicating ongoing challenges in its market position.
Zim Laboratories Faces Significant Selling Pressure with 36.46% Yearly Loss and Persistent Decline
Zim Laboratories Ltd is experiencing significant selling pressure, continuing a trend of consecutive losses. The stock has underperformed compared to the Sensex over various time frames, with notable declines over the past year and three years. It is also trading below multiple moving averages, indicating ongoing challenges.
Why is Zim Laboratories falling/rising?
As of 30-Oct, Zim Laboratories Ltd's stock price is Rs 74.37, down 10.11% and significantly underperforming its sector. Despite increased investor participation, the stock has declined 30.79% over the past year, contrasting with the Sensex's 5.58% gain.
Why is Zim Laboratories falling/rising?
As of 29-Oct, Zim Laboratories Ltd's stock price is Rs 82.73, up 19.85% recently, but it has declined 22.68% year-to-date. Despite a short-term rebound, the stock shows mixed investor sentiment with significantly decreased trading volume.
Zim Laboratories Ltd Gains 0.25% Today, Reaches Intraday High Amid Ongoing Price Declines
Zim Laboratories Ltd is experiencing notable buying activity, with a modest gain today and a slight increase over the past week. However, the stock has faced challenges in the longer term, showing declines over the past month and three months. Its current price is approaching a critical support level.
Zim Laboratories Stock Plummets to New 52-Week Low at Rs. 65
Zim Laboratories has reached a new 52-week low, reflecting ongoing challenges for the microcap pharmaceutical company. The stock has consistently underperformed its sector, with significant declines in net sales and a low return on capital employed. The company has reported negative results for five consecutive quarters.
Zim Laboratories Stock Hits New 52-Week Low at Rs. 65
Zim Laboratories has reached a new 52-week low, reflecting ongoing challenges in the Pharmaceuticals & Biotechnology sector. The company has seen a significant decline in stock price over the past year, with notable decreases in net sales and profit after tax, indicating persistent market weakness.
Zim Laboratories Hits New 52-Week Low at Rs. 68.05
Zim Laboratories has reached a new 52-week low, reflecting ongoing challenges in its financial health. The company has underperformed its sector and is trading below key moving averages. Over the past year, it has seen a significant decline in net sales and negative results for five consecutive quarters.
Zim Laboratories Hits New 52-Week Low at Rs. 68.05
Zim Laboratories has reached a new 52-week low, reflecting a significant downturn in its stock performance. The company has consistently underperformed its sector and has faced a substantial decline over the past year. Financial metrics indicate ongoing challenges, including declining net sales and profitability issues.
Zim Laboratories Faces Significant Selling Pressure with 42.46% Decline Over Last Three Months
Zim Laboratories Ltd is experiencing notable selling pressure, marked by consecutive losses and a significant decline over the past three months. The stock is trading near its 52-week low and remains below key moving averages, reflecting a challenging environment influenced by both market dynamics and company-specific factors.
Zim Laboratories Hits New 52-Week Low at Rs. 68.88
Zim Laboratories has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company has reported negative results for five consecutive quarters, with a notable drop in net sales and a decrease in return on capital employed, highlighting ongoing financial challenges.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
